INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS
The treatment of human subjects exposed to, or potentially exposed to SARS-CoV-2 virus, or suffering from COVID-19, comprises the step of administering to the human subjects a multiple-component antiviral formulation comprising a curcumin component, harmine component, and isovanillin component, and/...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English |
Published |
23.06.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The treatment of human subjects exposed to, or potentially exposed to SARS-CoV-2 virus, or suffering from COVID-19, comprises the step of administering to the human subjects a multiple-component antiviral formulation comprising a curcumin component, harmine component, and isovanillin component, and/or variants thereof. The formulation may also be used to inhibit SARS-CoV-2 virus in cell-based assays or in the manufacture of antiviral medicaments. |
---|---|
Bibliography: | Application Number: US202117559445 |